La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Heliogen a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Heliogen..

Heliogen (OTC:HLGNW) Azioni, Catena delle Opzioni

Heliogen Inc is a concentrated solar energy system that is being developed to unlock the power of sunlight to replace fossil fuels. Powered by artificial intelligence (AI), its modular system aims to deliver low-cost renewable energy in the form of heat, power, or hydrogen fuel.

Heliogen Inc

President-elect Donald Trump's nomination of former Democratic Congresswoman <a href="https://www.benzinga.com/topic/tulsi-gabbard">Tulsi Gabbard</a> as Director of National Intelligence (DNI) has sparked debate.
The selection drew mixed reactions due to her unconventional political background and history of controversial statements. Though, the <a href="https://www.benzinga.com/markets/cannabis/23/02/30743988/breaking-the-chains-of-cannabis-criminalization-tulsi-gabbards-fight-for-legalization-from-grine">cannabis industry isn&#8217;t complaining.</a>
If confirmed, Gabbard would become the highest-ranking intelligence official despite a lack of experience within the intelligence community. Her appointment marks a sharp departure from past presidential selections, as she has never served on a congressional intelligence committee.
A former Hawaii Army National Guard member who deployed to Iraq with a medical unit, Gabbard has frequently criticized U.S. foreign policy as overly aggressive and imperialistic. 
Her outspoken stances, including opposition to mainstream U.S. intelligence views on Russia, raise questions about how she will navigate her role overseeing the nation's 18 intelligence agencies with a combined budget of approximately $70 billion.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41982165/new-gop-senate-leader-john-thune-opposes-marijuana-legalization-implications-for-banking-access-and-more">New GOP Senate Leader John Thune Opposes Marijuana Legalization: Implications For Banking Access And More</a>
<h3 class="wp-block-heading">Cannabis Policy Contributions</h3>
Beyond foreign policy, Gabbard's legislative record includes notable contributions to cannabis reform, earning her broad support within the marijuana industry and advocacy groups. Over her eight years in Congress, she was as a vocal supporter of marijuana and hemp reform, introducing legislation that reflected her commitment to decriminalization and medicinal use.
In 2017, Gabbard introduced a bipartisan bill that sought to end federal prohibition by removing cannabis from the Controlled Substances Act, a landmark move that appealed to both sides of the aisle.
"Our archaic and outdated marijuana laws are turning everyday Americans into criminals," Gabbard <a href="https://norml.org/blog/2019/03/07/rep-tulsi-gabbard-i-just-introduced-legislation-to-end-the-federal-marijuana-prohibition/">said</a> at the time. "Every day, the economic and social impacts of marijuana prohibition are having devastating effects on communities across the country." 
Her advocacy extended to military service members. In 2020, she <a href="https://www.benzinga.com/markets/cannabis/20/07/16709095/congress-allows-troops-to-use-cbd-products-1">filed an amendment</a> to permit the use of hemp-derived CBD products, pushing back against the expanding ban on these products within the armed forces and Veterans Administration (VA).
<h3 class="wp-block-heading">Russia Propagandist? </h3>
Despite her legislative achievements and progressive stance on cannabis reform, Gabbard's alignment with the intelligence community's stance on Russia remains contentious. In recent years, she faced backlash from lawmakers who accused her of amplifying Russian propaganda after she shared a video referencing alleged U.S.-funded "bio labs" in Ukraine. The claim was widely debunked by U.S., Ukrainian officials and independent sources.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There are 25+ US-funded biolabs in Ukraine which if breached would release &amp; spread deadly pathogens to US/world. We must take action now to prevent disaster. US/Russia/Ukraine/NATO/UN/EU must implement a ceasefire now around these labs until they're secured &amp; pathogens destroyed <a href="https://t.co/dhDTH5smIG">pic.twitter.com/dhDTH5smIG</a>
&mdash; Tulsi Gabbard &#x1f33a; (@TulsiGabbard) <a href="https://twitter.com/TulsiGabbard/status/1502960938147729413?ref_src=twsrc%5Etfw">March 13, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41992074/trump-says-his-secretary-of-state-pick-marco-rubio-is-powerful-voice-for-freedom-but-what-about-cannabis">Trump Says His Secretary Of State Pick Marco Rubio Is &#8216;Powerful Voice For Freedom&#8217; – But What About Cannabis?</a></li>
</ul>
Photo: <a href="https://www.flickr.com/people/22007612@N05">Gage Skidmore</a>, <a href="https://en.wikipedia.org/wiki/en:Creative_Commons">Creative Commons</a>&nbsp;<a href="https://creativecommons.org/licenses/by-sa/2.0/deed.en">Attribution-Share Alike 2.0</a>/Wikipedia

Cannabis

Government

News

Politics

Legal

Trump's National Intelligence Pick Is Cannabis Advocate Tulsi Gabbard: Critics Say Former Congresswoman Parrots Russia Propaganda

Earnings

AIFF

Firefly Neuroscience Reports  Cash Of $1.2M As Of September 30, 2024

DA Davidson analyst Linda Bolton Weiser maintains Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) with a Buy and maintains $16 price target.

Price Target

Analyst Ratings

FNKO

DA Davidson Maintains Buy on Funko, Maintains $16 Price Target

Outlook
<ul>
<li>The Company anticipates Net Income will be approximately ($0.7) million in Q4 2024 and approximately ($0.7) million in Q1 2025, representing substantial increases driven by a reduction in operating and interest expenses due to the recently announced $28.8 million debt restructuring and $13.5 million Net Income Improvement initiative.</li>
<li>The Company anticipates Adjusted EBITDA to be approximately ($1.4) million in Q4 2024, and approximately ($1.1) million in Q1 2025, representing substantially improved runway and progress towards profitability and positive cash-flow.</li>
</ul>
"It is hard to overstate how important the third quarter of 2024 was for Banzai," said Joe Davy, Founder and CEO of Banzai. "We believe this marks a turning point for the Company in many ways. Banzai achieved&nbsp;a 31% annualized&nbsp;Annual Recurring Revenue&nbsp;growth&nbsp;rate&nbsp;and a historic record for Net Revenue Retention. We also made game-changing improvements to our balance sheet and cost structure to set us up for sustainable profitability in the future. Growth was driven by our focus on the Reach product through re-engineering and expanded sales efforts, leading to the addition of 1,785 customers through October 2024. In total, we now serve nearly 3,000 customers that have contributed to top and bottom-line sequential improvements from the second quarter.
"To better serve our customers, we have continued to invest in our software platforms and growth. We've launched a new product, Curate, to bring AI-powered newsletters that leverage OpenAI's GPT-4o to automate the newsletter creation process by writing relevant, branded articles that resonate with target audiences. We added significant enhancements to our Demio platform through deeper integration with Salesforce, the industry leading AI CRM company, with key enhancements designed to maximize efficiency and insight, offering marketers a more scalable, data-rich experience. We also released a major improvement to the Demio HubSpot integration. This upgrade offers unparalleled flexibility and efficiency in managing webinar data, empowering marketers to streamline their webinar management and marketing efforts, leading to better decision-making and higher ROI.
"Alongside a $5.0 million private placement transaction and debt restructuring transactions we executed, we implemented a strategic initiative that we expect will enable us to significantly improve net income, substantially extend our cash runway and invest in growth. We are making significant progress on these goals and overall improvement in net income is expected to be approximately $12.2 million annually when fully implemented, while maintaining our growth outlook.
"Looking ahead, our ability to leverage deep analytics and insights to drive marketing decisions combined with leveraging AI to launch exciting new products and capabilities, will continue to drive growth. We will continue to manage costs efficiently while investing in our software platform, sales and marketing and product development. We look forward to additional updates on our anticipated milestones in the weeks and months to come," concluded Davy.
 &nbsp;

Guidance

BNZI

Banzai Anticipates Net Income Will Be ~($0.7M) In Q4 2024 And ~($0.7M) In Q1 2025, Representing Substantial Increases Driven By A Reduction In Operating And Interest Expenses Due To The Recently Announced $28.8M Debt Restructuring And $13.5M Net Income Improvement Initiative; Adjusted EBITDA To Be ~($1.4M) In Q4 2024, And ~($1.1M) In Q1 2025, Representing Substantially Improved Runway And Progress Towards Profitability And Positive Cash-Flow

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) reported financial results for the third quarter Thursday after the bell. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41990105/ast-spacemobile-provides-business-update-and-third-quarter-2024-results">key details from the report</a>.
Q3 Earnings:&nbsp;AST SpaceMobile&nbsp;reported&nbsp;third-quarter revenue of $1.1 million. The company reported an adjusted loss of $1.10 per share, missing&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;for a loss of 20 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Operating expenses for the&nbsp;third quarter&nbsp;totaled&nbsp;$66.6 million, up $2.7 million from the second quarter. The company ended the period with $518.9 million in cash, cash equivalents and restricted cash. 
&#8220;We achieved many significant milestones in the quarter and continue our momentum with several key pieces now in place,&#8221; said Abel Avellan, founder, chairman and CEO of AST SpaceMobile. 
&#8220;With the first five BlueBird satellites successfully unfolded and entering initial operations, our business is progressing according to plan. We&#8217;ve advanced our strategy across multiple efforts including progress on securing orbital launch capacity, growing our manufacturing capability, and expanding our customer ecosystem.&#8221;
AST SpaceMobile executives will hold a conference call at 5 p.m. ET to further discuss the quarter with investors.
See Also: <a href="https://www.benzinga.com/general/space/24/11/41961309/rocket-lab-ceo-touts-spacex-rival-status-trump-impact-on-space-as-stock-surges-almost-30">Rocket Lab CEO Touts SpaceX Rival Status, Trump Impact On Space As Stock Surges Almost 30%</a>
Service Agreements: AST SpaceMobile separately announced launch services agreements securing the orbital launch capacity to enable continuous space-based cellular broadband service coverage.
The company&#8217;s global service will initially target key markets including the U.S., Europe, Japan and other strategic markets.
The company&#8217;s next-gen Block 2 Bluebird satellites are expected to deliver up to 10 times the bandwidth capacity of the Bluebirds currently in orbit, and are designed to be compatible with all major launch vehicles.
&#8220;With these new launch services agreements, our in-house vertically integrated manufacturing capabilities in Texas, our mobile operator partners, and the additional capital raised during 2024, we are now well-positioned to reach our goal of continuous cellular broadband service coverage, enabling our service to hundreds of millions of users around the world and the U.S. government,&#8221; said Scott Wisniewski, president of AST SpaceMobile.
ASTS Price Action: <a href="http://benzinga.com/quote/asts" target="_blank" rel="noreferrer noopener">AST SpaceMobile shares</a>&nbsp;were down 13.47% after hours, trading at $23.19 at the time of publication Thursday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Courtesy of AST SpaceMobile.

SPACE

After-Hours Center

Movers

General

ASTS

AST SpaceMobile Misses Q3 Earnings Expectations, Announces New Launch Service Agreements

Banzai International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) reported quarterly losses of $(2.68) per share. This is a 712.12 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $1.08 million which missed the analyst consensus estimate of $1.20 million by 9.95 percent. This is a 2.51 percent decrease over sales of $1.11 million the same period last year.

Earnings Misses

Banzai International Q3 EPS $(2.68) Down From $(0.33) YoY, Sales $1.08M Miss $1.20M Estimate

FBYD

Falcons Beyond Global Q3 EPS $0.46, Sales $2.07M Up From $1.58M YoY

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and maintains $7 price target.

TSHA

Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $7 Price Target

Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) reported quarterly earnings of $0.02 per share. This is a 100.14 percent increase over losses of $(14.15) per share from the same period last year. The company reported $132.00 thousand in sales this quarter. This is a 221.95 percent increase over sales of $41.00 thousand the same period last year.

ADGM

Adagio Medical Holdings Q3 EPS $0.02 Up From $(14.15) YoY, Sales $132.00K Up From $41.00K YoY

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $55 price target.

CRVO

Chardan Capital Maintains Buy on CervoMed, Maintains $55 Price Target

The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

HALO

Evotec Confirms Receipt Of Non-binding Expression Of Interest From Halozyme Therapeutics With An Offer Price Of EUR 11.00 Per Share

PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. The company reported quarterly sales of $9.100 million which beat the analyst consensus estimate of $8.859 million by 2.72 percent. This is a 24.15 percent increase over sales of $7.330 million the same period last year.

Earnings Beats

PEDEVCO Q3 2024 GAAP EPS $0.03 Beats $0.01 Estimate, Sales $9.100M Beat $8.859M Estimate

Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) reported quarterly losses of $(4.54) per share which beat the analyst consensus estimate of $(7.12) by 36.24 percent. This is a 30.9 percent increase over losses of $(6.57) per share from the same period last year.

FBRX

Forte Biosciences Q3 EPS $(4.54) Beats $(7.12) Estimate

Jefferies analyst Omar Nokta maintains Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) with a Buy and maintains $6 price target.

Jefferies Maintains Buy on Safe Bulkers, Maintains $6 Price Target

Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 47.92 percent increase over losses of $(0.48) per share from the same period last year.

RVPH

Reviva Pharmaceuticals Q3 2024 GAAP EPS $(0.25) Beats $(0.26) Estimate

Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) reported quarterly losses of $(0.72) per share. This is a 13.25 percent increase over losses of $(0.83) per share from the same period last year. The company reported $2.62 million in sales this quarter. This is a 5.65 percent increase over sales of $2.48 million the same period last year.

NVFY

Nova Lifestyle Q3 EPS $(0.72) Up From $(0.83) YoY, Sales $2.62M Up From $2.48M YoY

Hedge Funds

FLUT

SPOT

ValueAct Holdings' Q3 2024 13F Filing Reveals Full Exits From Spotify, Fiserv, KKR & Co., New York Times With 1.34M Shares, And Flutter Entertainment

COLL

COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced it will transfer its stock listing <a href="https://www.benzinga.com/pressreleases/24/11/b41988795/palantir-announces-transfer-of-stock-exchange-listing-to-nasdaq">to the Nasdaq</a>.
What Happened: After the market close on Thursday, Palantir announced that it would transfer the listing of its Class A common stock from the New York Stock Exchange to the Nasdaq Global Select Market.
Palantir said it expects to begin trading as a Nasdaq-listed company on Nov. 26. The stock will continue to trade under the ticker symbol &#8220;PLTR.&#8221;
&#8220;Upon transferring, Palantir anticipates meeting the eligibility requirements of the Nasdaq-100 Index,&#8221; the company said.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a>
Palantir has been one of the hottest stocks of the year, having gained approximately 245% year-to-date, driven by the company&#8217;s positioning in the <a href="http://benzinga.com/topic/ai">AI</a> space. 
Palantir shares really took off at the beginning of November after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">strong quarterly results</a> driven by&nbsp;"unrelenting" AI demand. 
Revenue jumped 30% year-over-year on continued strength in the U.S. customer count grew 39% year-over-year after the company closed 104 deals worth over $1 million during the quarter.
"The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,&#8221;&nbsp;Alex Karp, co-founder and CEO of Palantir, said in a letter to shareholders.
PLTR Price Action: Palantir shares were up 3.87% in after-hours, trading at $61.47 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Tech

PLTR

Palantir Stock Is Rising After The Bell: What's Going On?

Trading Ideas

GOOG

GOOGL

Pershing Square Capital's Q3 2024 13F Filing Reveals Reduced Stakes In Hilton Worldwide By 18% To 7.37M Shares, Chipotle Mexican Grill By 8%, Restaurant Brands Intl By 1% To 23.0M Shares, And Alphabet Class C And Class A By 9%

Comments

Heliogen

Heliogen (HLGNW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO